• Ken Herrmann, Christina Bluemel, Martina Weineisen, Margret Schottelius, Hans-Jürgen Wester, Johannes Czernin, Uta Eberlein, Seval Beykan, Constantin Lapa, Hubertus Riedmiller, Markus Krebs, Saskia Kropf, Andreas Schirbel, Andreas K Buck, and Michael Lassmann.
• Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, Los Angeles, California Herrmann_K1@ukw.de.
• J. Nucl. Med. 2015 Jun 1; 56 (6): 855-61.

UnlabelledProstate-specific membrane antigen (PSMA) is a promising target for diagnosis and treatment of prostate cancer. EuK-Subkff-(68)Ga-DOTAGA ((68)Ga-PSMA Imaging & Therapy [PSMA I&T]) is a recently introduced PET tracer for imaging PSMA expression in vivo. Whole-body distribution and radiation dosimetry of this new probe were evaluated.MethodsFive patients with a history of prostate cancer were injected intravenously with 91-148 MBq of (68)Ga-PSMA I&T (mean ± SD, 128 ± 23 MBq). After an initial series of rapid whole-body scans, 3 static whole-body scans were acquired at 1, 2, and 4 h after tracer injection. Time-dependent changes of the injected activity per organ were determined. Mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM.ResultsInjection of 150 MBq of (68)Ga-PSMA I&T resulted in an effective dose of 3.0 mSv. The kidneys were the critical organ (33 mGy), followed by the urinary bladder wall and spleen (10 mGy each), salivary glands (9 mGy each), and liver (7 mGy).Conclusion(68)Ga-PSMA I&T exhibits a favorable dosimetry, delivering organ doses that are comparable to (kidneys) or lower than those delivered by (18)F-FDG.© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

37 keywords...

hide…